Osiris Therapeutics, Inc.
http://www.osiris.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Osiris Therapeutics, Inc.
Stock Watch: The Cost And Risks Of Pharmaceutical Success
Presenting at conferences allows companies to showcase data on new drugs and secure licensing partners, as well as further investment by shareholders. But two presentations at the recent EHA conference had the opposite effect.
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.
Gossamer Partners With Chiesi To Accelerate Seralutinib Development
Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice